Temozolomide-d3
CAT:
804-HY-17364S
Size:
1 mg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Temozolomide-d3
Description:
Temozolomide-d3 is the deuterium labeled Temozolomide. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].UNSPSC:
12352005Hazard Statement:
H302, H340, H350, H360, H412Target:
Apoptosis; Autophagy; DNA Alkylator/CrosslinkerType:
Isotope-Labeled CompoundsRelated Pathways:
Apoptosis; Autophagy; Cell Cycle/DNA DamageApplications:
Cancer-programmed cell deathField of Research:
CancerPurity:
99.87Solubility:
10 mM in DMSO|DMF : ≥ 5mg/mL|DMSO : ≥ 5mg/mLSmiles:
O=C (N1C=N2) N (N=NC1=C2C (N) =O) C ([2H]) ([2H]) [2H]Molecular Formula:
C6H3D3N6O2Molecular Weight:
197.17Precautions:
H302, H340, H350, H360, H412References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Tentori L, et al. Combined treatment with temozolomide and poly (ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99 (6) :2241-4.|[3]Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10 (10) :e0140131.|[4]Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10 (12) :1383-92.Shipping Conditions:
Blue IceStorage Conditions:
-20°C, 3 years (Powder)Scientific Category:
Isotope-Labeled CompoundsClinical Information:
No Development ReportedCAS Number:
208107-14-6
